ImmunityBio, Inc. $IBRX Shares Sold by Clearwater Capital Advisors LLC

Clearwater Capital Advisors LLC lessened its holdings in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 15.1% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 717,524 shares of the company’s stock after selling 127,560 shares during the period. Clearwater Capital Advisors LLC owned 0.07% of ImmunityBio worth $5,503,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of IBRX. Vanguard Group Inc. lifted its holdings in shares of ImmunityBio by 18.5% in the 4th quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company’s stock worth $64,899,000 after purchasing an additional 5,122,052 shares during the last quarter. State Street Corp lifted its stake in ImmunityBio by 45.4% in the fourth quarter. State Street Corp now owns 16,455,703 shares of the company’s stock valued at $32,582,000 after buying an additional 5,139,890 shares during the last quarter. Geode Capital Management LLC lifted its stake in ImmunityBio by 15.0% in the fourth quarter. Geode Capital Management LLC now owns 7,920,178 shares of the company’s stock valued at $15,684,000 after buying an additional 1,030,113 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of ImmunityBio by 439.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company’s stock valued at $12,182,000 after acquiring an additional 5,012,001 shares during the period. Finally, Woodline Partners LP grew its position in shares of ImmunityBio by 53.7% during the third quarter. Woodline Partners LP now owns 5,297,725 shares of the company’s stock worth $13,032,000 after acquiring an additional 1,851,854 shares during the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

Insiders Place Their Bets

In related news, Director Barry J. Simon sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $7.88, for a total transaction of $197,000.00. Following the transaction, the director owned 2,802,788 shares in the company, valued at $22,085,969.44. This trade represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 131,210 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $9.50, for a total value of $1,246,495.00. Following the sale, the director directly owned 125,386 shares in the company, valued at approximately $1,191,167. The trade was a 51.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 435,443 shares of company stock worth $3,918,819. 66.10% of the stock is owned by corporate insiders.

ImmunityBio Stock Performance

Shares of IBRX opened at $7.51 on Thursday. The firm has a market capitalization of $7.87 billion, a price-to-earnings ratio of -8.84 and a beta of 0.01. ImmunityBio, Inc. has a one year low of $1.95 and a one year high of $12.43. The stock’s fifty day moving average is $7.80 and its 200-day moving average is $7.32.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.54). The company had revenue of $44.21 million for the quarter, compared to analyst estimates of $43.07 million. Analysts forecast that ImmunityBio, Inc. will post -0.31 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on IBRX shares. BTIG Research reiterated a “buy” rating and issued a $12.00 price objective on shares of ImmunityBio in a research report on Thursday, May 21st. D. Boral Capital restated a “buy” rating and issued a $23.00 target price on shares of ImmunityBio in a research report on Tuesday, May 5th. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a research report on Friday, July 10th. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of ImmunityBio in a research note on Tuesday, June 2nd. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.20.

ImmunityBio Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.